The drug and vaccine maker previously announced it was a victim of the international hacking scheme, but hadn't disclosed the effect on manufacturing until it released second quarter earnings Friday. Merck is still working to restore manufacturing processes and doesn't know the full impact of the production issues yet.
Merck's profit still improved, rising to $1.95 billion in the second quarter, up from $1.21 billion during the same period last year.
Merck told investors it is confident that its life-saving bestsellers Keytruda, Januvia and Zepatier will continue in normal supplies. It's unsure about some other unnamed products.
Merck stock traded slightly up in early afternoon.
More of What's Trending on TheStreet:
- Amazon and General Electric Are Friday's Smoking Hot Tickers: AMZN, TSLA, SBUX, GE, AAPL
- Starbucks Shares Are Crashing; Go Out and Buy!
- Amazon's Stock Falls on Big Second-Quarter Earnings Miss: What Wall Street's Saying
- Tesla's Model 3 Arrives on Friday -- Here's Everything You Need to Know About This Over-Hyped Ride